{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:32:43Z","timestamp":1790195563810,"version":"4.1.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold>Sodium glucose cotransporter 2 inhibitors (SGLT2-is) are antidiabetic drugs that improve glycemic control by limiting urinary glucose reuptake in the proximal tubule. SGLT2-is might suppress atherosclerotic processes and ameliorate the prognosis of patients with diabetes mellitus diagnosed with or at high risk of atherosclerotic cardiovascular disease (ASCVD). In this mini review, we examine the role of SGLT2-is in the development and progression of atherosclerosis throughout its spectrum, from subclinical atherosclerosis to ASCVD.<\/jats:p><jats:p><jats:bold>Data Sources<\/jats:bold>\u2014PubMed and Google Scholar were searched for publications related to SGLT2-is and atherosclerosis. All types of articles were considered, including clinical trials, animal studies,<jats:italic>in vitro<\/jats:italic>observations, and reviews and meta-analyses. Data were examined according to their impact and clinical relevance.<\/jats:p><jats:p><jats:bold>Synopsis of Content<\/jats:bold>\u2014We first review the underlying mechanisms of SGLT2-is on the development and progression of atherosclerosis, including favorable effects on lipid metabolism, reduction of systemic inflammation, and improvement of endothelial function. We then discuss the putative impact of SGLT2-is on the formation, composition, and stability of atherosclerotic plaque. Furthermore, we evaluate the effects of SGLT2-is in subclinical atherosclerosis assessed by carotid intima media thickness and pulse wave velocity. Subsequently, we summarize the effects of SGLT2-is in ASCVD events, including ischemic stroke, angina pectoris, myocardial infarction, revascularization, and peripheral artery disease, as well as major adverse cardiovascular events, cardiovascular mortality, heart failure, and chronic kidney disease. Moreover, we examine factors that could modify the role of SGLT2-is in atherosclerosis, including sex, age, diabetes, glycemic control, ASCVD, and SGLT2-i compounds. Additionally, we propose future directions that can improve our understanding of SGLT2-is and atherosclerosis.<\/jats:p>","DOI":"10.3389\/fphar.2021.751214","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T09:13:17Z","timestamp":1636103597000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Aur\u00e9lie","family":"Pahud de Mortanges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dante","family":"Salvador Jr.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Laimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taulant","family":"Muka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjola","family":"Bano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.2337\/dc16-s011","article-title":"8. Cardiovascular Disease and Risk Management","volume":"39","year":"2016","journal-title":"Dia Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.jacc.2019.08.012","article-title":"From Subclinical Atherosclerosis to Plaque Progression and Acute Coronary Events: JACC State-Of-The-Art Review","volume":"74","author":"Ahmadi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2018.02.028","article-title":"SGLT2 Inhibition Reduces Atherosclerosis by Enhancing Lipoprotein Clearance in Ldlr-\/- Type 1 Diabetic Mice","volume":"271","author":"Al-Sharea","year":"2018","journal-title":"Atherosclerosis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of Plaque Formation and Rupture","volume":"114","author":"Bentzon","year":"2014","journal-title":"Circ. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients with and without Peripheral Artery Disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.dsx.2019.01.016","article-title":"Lipid Profile in Type 2 Diabetic Patients with New Dapagliflozin Treatment; Actual Clinical Experience Data of Six Months Retrospective Lipid Profile from Single center","volume":"13","author":"Calapkulu","year":"2019","journal-title":"Diabetes Metab. Syndr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1590\/1806-9282.65.1.70","article-title":"Inhibition of the Sodium-Glucose Co-transporter 2 in the Elderly: Clinical and Mechanistic Insights into Safety and Efficacy","volume-title":"Revista da Associacao Medica Brasileira","author":"Cintra","year":"2019"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/bmjopen-2012-001007","article-title":"Systematic Review of SGLT2 Receptor Inhibitors in Dual or Triple Therapy in Type 2 Diabetes","volume":"2","author":"Clar","year":"2012","journal-title":"BMJ Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11010-019-03555-2","article-title":"Empagliflozin Restores the Integrity of the Endothelial Glycocalyx In Vitro","volume":"459","author":"Cooper","year":"2019","journal-title":"Mol. Cel Biochem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1042\/BCJ20200278","article-title":"The SGLT2 Inhibitor Canagliflozin Suppresses Lipid Synthesis and Interleukin-1 Beta in ApoE Deficient Mice","volume":"477","author":"Day","year":"2020","journal-title":"Biochem. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.diabres.2019.05.028","article-title":"Peripheral Artery Disease and Amputations with Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors: A Meta-Analysis of Randomized Controlled Trials","volume":"153","author":"Dicembrini","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"110487","DOI":"10.1016\/j.mce.2019.110487","article-title":"Empagliflozin Improves Primary Haemodynamic Parameters and Attenuates the Development of Atherosclerosis in High Fat Diet Fed APOE Knockout Mice","volume":"494","author":"Dimitriadis","year":"2019","journal-title":"Mol. Cel Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/archinte.168.12.1333","article-title":"Coronary Artery Calcification Compared with Carotid Intima-media Thickness in the Prediction of Cardiovascular Disease Incidence: The Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"168","author":"Folsom","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"173040","DOI":"10.1016\/j.ejphar.2020.173040","article-title":"Empagliflozin Ameliorates Endothelial Dysfunction and Suppresses Atherogenesis in Diabetic Apolipoprotein E-Deficient Mice","volume":"875","author":"Ganbaatar","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(20)30038-3","article-title":"Glucose-lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People with or at Risk of Type 2 Diabetes: an Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome Trials","volume":"8","author":"Ghosh-Swaby","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B17","first-page":"1046","article-title":"Writing Committee Members Cholesterol Clinical Practice Guidelines 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/ APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary Circulation","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The Beneficial Effects of Empagliflozin, an SGLT2 Inhibitor, on Atherosclerosis in ApoE -\/- Mice Fed a Western Diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12933-017-0608-5","article-title":"Correction to: Dapagliflozin Decreases Small Dense Low-Density Lipoprotein-Cholesterol and Increases High-Density Lipoprotein 2-cholesterol in Patients with Type 2 Diabetes: Comparison with Sitagliptin","volume":"16","author":"Hayashi","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin Reduces Inflammation and Fibrosis Biomarkers: a Potential Mechanism of Action for Beneficial Effects of SGLT2 Inhibitors in Diabetic Kidney Disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0234065","DOI":"10.1371\/journal.pone.0234065","article-title":"Association between Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Lower Extremity Amputation: A Systematic Review and Meta-Analysis","volume":"15","author":"Heyward","year":"2020","journal-title":"PLOS ONE"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1111\/dom.14159","article-title":"Sodium-glucose Co-transporter-2 Inhibitors and Major Adverse Limb Events: A Trial-Level Meta-Analysis Including 51 713 Individuals","volume":"22","author":"Huang","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1111\/dom.13740","article-title":"Navigating the \"MACE\" in Cardiovascular Outcomes Trials and Decoding the Relevance of Atherosclerotic Cardiovascular Disease Benefits versus Heart Failure Benefits","volume":"21","author":"Hupfeld","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e015716","DOI":"10.1161\/JAHA.119.015716","article-title":"Effects of Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients with Type 2 Diabetes Mellitus after 12-Month Treatment","volume":"9","author":"Ikonomidis","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","article-title":"Improvement in Cardiovascular Outcomes with Empagliflozin Is Independent of Glycemic Control","volume":"138","author":"Inzucchi","year":"2018","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.106.613281","article-title":"Suppression of Atherosclerotic Plaque Progression and Instability by Tissue Inhibitor of Metalloproteinase-2: Involvement of Macrophage Migration and Apoptosis","volume":"113","author":"Johnson","year":"2006","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1179551419866811","DOI":"10.1177\/1179551419866811","article-title":"Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes","volume":"12","author":"Kamijo","year":"2019","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"B29","doi-asserted-by":"publisher","first-page":"106779","DOI":"10.1016\/j.vph.2020.106779","article-title":"Anti-inflammatory Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Atherosclerosis","author":"Kang","year":"2020","journal-title":"Vasc. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12933-020-01079-4","article-title":"Tofogliflozin Does Not Delay Progression of Carotid Atherosclerosis in Patients with Type 2 Diabetes: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study","volume":"19","author":"Katakami","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12933-020-01206-1","article-title":"Effect of Tofogliflozin on Arterial Stiffness in Patients with Type 2 Diabetes: Prespecified Sub-analysis of the Prospective, Randomized, Open-Label, Parallel-Group Comparative UTOPIA Trial","volume":"20","author":"Katakami","year":"2021","journal-title":"Cardiovasc. Diabetology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4070\/kcj.2019.0296","article-title":"Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model","volume":"50","author":"Lee","year":"2020","journal-title":"Korean Circ. J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"6305735","DOI":"10.1155\/2016\/6305735","article-title":"The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-\/- Mice","volume":"2016","author":"Leng","year":"2016","journal-title":"Mediators Inflamm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1172\/JCI13005","article-title":"VCAM-1 Is Critical in Atherosclerosis","volume":"107","author":"Ley","year":"2001","journal-title":"J. Clin. Invest."},{"key":"B35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12944-021-01430-y","article-title":"Empagliflozin Protects against Atherosclerosis Progression by Modulating Lipid Profiles and Sympathetic Activity","volume":"20","author":"Liu","year":"2021","journal-title":"Lipids Health Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/35025203","article-title":"Atherosclerosis","volume":"407","author":"Lusis","year":"2000","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.ultrasmedbio.2007.01.018","article-title":"On the Potential of the Lagrangian Estimator for Endovascular Ultrasound Elastography: In Vivo Human Coronary Artery Study","volume":"33","author":"Maurice","year":"2007","journal-title":"Ultrasound Med. Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes: A Meta-Analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.2174\/1871529X18666180206120444","article-title":"Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke","volume":"18","author":"Milonas","year":"2018","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets"},{"key":"B41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/labinvest.3780446","article-title":"Leukocyte-Endothelial Cell Interactions in the Inflammatory Response","volume":"82","author":"Muller","year":"2002","journal-title":"Lab. Invest."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3390\/ijms18081704","article-title":"The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice","volume":"18","author":"Nakatsu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","article-title":"Canagliflozin Attenuates the Progression of Atherosclerosis and Inflammation Process in APOE Knockout Mice","volume":"17","author":"Nasiri-Ansari","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 Inhibitors for the Prevention of Kidney Failure in Patients with Type 2 Diabetes: a Systematic Review and Meta-Analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s00125-021-05399-2","article-title":"The Efficacy and Safety of Dapagliflozin in Women and Men with Type 2 Diabetes Mellitus","volume":"64","author":"O\u2019Donoghue","year":"2021","journal-title":"Diabetologia"},{"key":"B47","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.4049\/jimmunol.147.9.2913","article-title":"Differential Utilization of ICAM-1 and VCAM-1 during the Adhesion and Transendothelial Migration of Human T Lymphocytes","volume":"147","author":"Oppenheimer-Marks","year":"1991","journal-title":"J. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12933-021-01252-3","article-title":"Angiotensin II-Induced Upregulation of SGLT1 and 2 Contributes to Human Microparticle-Stimulated Endothelial Senescence and Dysfunction: Protective Effect of Gliflozins","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"17937","DOI":"10.1038\/s41598-019-54224-9","article-title":"Glucose Lowering by SGLT2-Inhibitor Empagliflozin Accelerates Atherosclerosis Regression in Hyperglycemic STZ-Diabetic Mice","volume":"9","author":"Pennig","year":"2019","journal-title":"Sci. Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/dom.13876","article-title":"Effects of Sodium-Glucose Co-transporter-2 Inhibitors in Type 2 Diabetes in Women versus Men","volume":"22","author":"R\u00e5dholm","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/PHAR.1010","article-title":"Dapagliflozin: a Novel Sodium-Glucose Cotransporter Type 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus","volume":"32","author":"Shah","year":"2012","journal-title":"Pharmacotherapy"},{"key":"B55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.diabres.2019.02.014","article-title":"Meta-analyses of the Effects of DPP-4 Inhibitors, SGLT2 Inhibitors and GLP1 Receptor Analogues on Cardiovascular Death, Myocardial Infarction, Stroke and Hospitalization for Heart Failure","volume":"150","author":"Sinha","year":"","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B56","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s13300-019-0597-3","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis","volume":"10","author":"Sinha","year":"","journal-title":"Diabetes Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12933-020-01016-5","article-title":"Sodium-glucose Cotransporter 2 Inhibitors Antagonize Lipotoxicity in Human Myeloid Angiogenic Cells and ADP-dependent Activation in Human Platelets: Potential Relevance to Prevention of Cardiovascular Events","volume":"19","author":"Spigoni","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e0166125","DOI":"10.1371\/journal.pone.0166125","article-title":"Benefits and Harms of Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"11","author":"Storgaard","year":"2016","journal-title":"PLoS One"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e0143396","DOI":"10.1371\/journal.pone.0143396","article-title":"Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice","volume":"10","author":"Terasaki","year":"2015","journal-title":"PLoS One"},{"key":"B60","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/hjh.0b013e32834fa8b0","article-title":"Expert Consensus Document on the Measurement of Aortic Stiffness in Daily Practice Using Carotid-Femoral Pulse Wave Velocity","volume":"30","author":"Van Bortel","year":"2012","journal-title":"J. Hypertens."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 Inhibitors and Mechanisms of Cardiovascular Benefit: a State-Of-The-Art Review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction: a Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors with All-Cause Mortality in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"key":"B65","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/0003319717742544","article-title":"Carotid-Femoral Pulse Wave Velocity in the Prediction of Cardiovascular Events and Mortality: An Updated Systematic Review and Meta-Analysis","volume":"69","author":"Zhong","year":"2018","journal-title":"Angiology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S2213-8587(19)30422-X","article-title":"Association of Glucose-Lowering Medications with Cardiovascular Outcomes: an Umbrella Review and Evidence Map","volume":"8","author":"Zhu","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.751214\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T14:31:58Z","timestamp":1673706718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.751214\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":67,"alternative-id":["10.3389\/fphar.2021.751214"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.751214","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"article-number":"751214"}}